|
Liver carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
ADC, mainly ADC<sub>oscillating</sub> , increased in the group of nodules with intermediate malignancy (ADC<sub>pulsed</sub> : 0.75 ± 0.25 × 10<sup>-3</sup> mm<sup>2</sup> /s vs. 0.64 ± 0.07 × 10<sup>-3</sup> mm<sup>2</sup> /s in benign nodules, P = 0.025; ADC<sub>oscillating</sub> : 0.81 ± 0.20 × 10<sup>-3</sup> mm<sup>2</sup> /s vs. 0.65 ± 0.13 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.0008) and ADC<sub>pulsed</sub> decreased in the group of progressed hepatocellular carcinomas (ADC<sub>pulsed</sub> : 0.60 ± 0.08 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.042; ADC<sub>oscillating</sub> : 0.68 ± 0.08 × 10<sup>-3</sup> mm<sup>2</sup> /s, P = 0.1).
|
31507025 |
2020 |
|
Liver carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Pre-operative ADC predicts early recurrence of HCC after curative resection.
|
30027408 |
2019 |
|
Liver carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
• The optimal cutoff values of ADC, D, D*, and f for predicting recurrence in HBV associated HCC were 0.858 × 10<sup>-3</sup> mm<sup>2</sup>/s, 0.985 × 10<sup>-3</sup> mm<sup>2</sup>/s, 12.5 × 10<sup>-3</sup> mm<sup>2</sup>/s, and 23.4%, respectively.
|
30972544 |
2019 |
|
Liver carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Multivariate analysis revealed that reverse target sign on hepatobiliary phase in FNHs (p = 0.009), iso or hyperintensity on ADC map in FNHs and HCAs (p = 0.009, < 0.001, respectively), central hypointensity on arterial phase in NETs (p = 0.001), hepatobiliary target sign in ICCs (p = 0.002), the presence of septum and capsule in HCCs (all p < 0.001) were significant independent features of each tumor group over other tumor groups.
|
31134313 |
2019 |
|
Liver carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Prediction of hepatocellular carcinoma response to <sup>90</sup>Yttrium radioembolization using volumetric ADC histogram quantification: preliminary results.
|
31142363 |
2019 |
|
Liver carcinoma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The proposed fusion of deep features derived from logb0, logb100, and logb600 with deeply supervised loss function generated the highest accuracy for HCC grading (80%), thus outperforming the method of deep feature derived from the ADC map directly (72.5%), the original b0 (65%), b100 (68%), and b600 (70%) images.
|
31169907 |
2019 |
|
Liver carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
In patients with two HCC lesions, highly similar ADC values for the two HCC lesions may be a preoperative predictor of MVI.
|
29392365 |
2018 |
|
Liver carcinoma
|
0.090 |
Biomarker
|
disease |
BEFREE |
In general ADC values can help discriminate between AE and hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
|
29110943 |
2018 |
|
Liver carcinoma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Our data show that an extended panel of immunohistochemical markers can reclassify around 60% of LCCs as ADC or SQCC.
|
22031317 |
2011 |